Abstract
Kidney transplantation is preferable treatment of children with end-stage kidney disease. All kidney transplant recipients including pediatric need immunosuppressive medications to prevent rejection episodes and graft loss.
Induction therapy is used temporarily only immediately following transplantation while maintenance immunosuppressive drugs are started and given long-term. There is currently no consensus regarding the use of induction therapy in children, its use should be decided based on the immunological risk of the child.
The recent progress shows that the recommended strategy is to use as maintenance immunosuppressive therapy a combination of a calcineurin inhibitor (preferably tacrolimus) with an antiproliferative drug (preferably mycophenolate mofetil) with steroids that can be withdrawn early or late in low-risk children. The mTOR-inhibitors (sirolimus, everolimus) are use rarely in pediatrics because of common side effects and no evidence of a benefit over calcineurin inhibitors.
The use of calcineurin inhibitors, mycophenolate and mTOR-inhibitors should be followed by therapeutic drug monitoring. Immunosuppressive therapy of acute rejection consists of high-dose steroids and/or anti-lymphocyte antibodies (T-cell mediated rejection) or plasma exchange, intravenous immunoglobulines and/or rituximab (antibody mediated rejection).
The future strategies for research are mainly precise characterisation of children needing induction therapy, more specific indications for mTOR-inhibitors and for the far future the possibility to reach the immuno tolerance.